Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in children and adolescents with systemic juvenile idiopathic arthritis
MOH_2019-11-04_007472Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic juvenile idiopathic arthritis (SJIA) comparing Tocilizumab arm with Baricitinib arm (2 arms). Started Sep 2019; status: recruiting.
02
Drugs
baricitinibtocilizumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on MOH_2019-11-04_007472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-11-04_007472.